JURA Bio
JURA Bio is pioneering AI-native drug discovery by bridging the gap between computational design and physical reality in biological AI. Their mission is to revolutionize the discovery and development of safe and effective drugs, making even the hardest therapeutic targets tractable. By leveraging manufacturing-aware generative models, JURA Bio not only designs new therapeutics but also builds, tests, and learns from them at unprecedented scale. Their approach integrates machine learning, synthetic biology, and high-throughput experimentation to create a new paradigm in drug discovery, where AI learns from tens of billions of real protein interactions and every candidate is inherently human-safe.
Patents
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
2025-09-23 • US-12421293-B2
View DetailsMajor histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
2023-11-28 • US-11826385-B2
View DetailsWhat We Do
A manufacturing-aware generative AI model architecture for biological sequence models, enabling the design and synthesis of quadrillions of novel protein sequences both in silico and in vitro. This technology dramatically reduces the cost of gene synthesis and accelerates the development of new generative models and therapeutics.
A system for creating high-quality, AI-ready functional biological data loops at massive scale. VISTA uses AI models to generate and test large in vitro datasets, particularly for antibody and CAR-based therapies, enabling the discovery of novel candidates against challenging oncology targets.
A system for accelerating AI training on functional biological data by incorporating knowledge of the underlying synthetic library into the training objective, resulting in dramatic speedups in learning and improved model performance for therapeutic discovery.
A method to estimate the effects of T cell receptors (TCRs) in humans using repertoire sequencing data and clinical outcomes, informing the design of TCR-T cell therapies, TCR bispecifics, and other emerging TCR-based medicines.
JURA Bio offers an AI-native drug discovery platform that integrates manufacturing-aware generative models, enabling the design, building, testing, and learning from new therapeutics at scale. Their platform is capable of generating and validating candidates for challenging targets, especially in oncology, using real-world protein interaction data.
JURA Bio collaborates with partners to discover and develop innovative immune-based therapies, leveraging their AI and synthetic biology expertise to generate high-quality immune receptor libraries and accelerate therapeutic development.
Application Area
Digital Health Technologies
Services
Key People
Head of Machine Learning
Head of R&D Ops
Co-Head of R&D
News & Updates
JURA Bio demonstrated the first AI-driven generation of antibody-based scFvs that specifically target peptide-HLA complexes, expanding the landscape of druggable intracellular targets.
JURA Bio introduced variational synthesis, enabling the design and synthesis of quadrillions of protein sequences at a fraction of previous costs, representing a trillion-fold reduction in gene synthesis cost.
JURA Bio's ML-improved gene synthesis technology generated a library of 100 billion potential TCR candidates, leading to the discovery of high-value TCRs for prostate cancer and other key neoantigen targets.
Coverage of JURA Bio's VISTA platform and its impact on large-scale antibody design using AI.
Discussion on the implications of JURA Bio's advances in DNA synthesis for drug discovery.
JURA Bio recognized as a notable company in the AI drug discovery space.